Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Trading 02-19 09:34:29 EST

454.22

-37.27

-7.58%

High461.50	Low445.33	Vol114.08K
Open452.02	D1 Closing491.49	Amplitude3.29%
Mkt Cap10.32B	Tradable Cap5.00B	Total Shares22.71M
T/O51.49M	T/O Rate1.04%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":454.215,"timestamp":1771511665883,"preClose":491.49,"halted":0,"volume":114077,"delay":0,"changeRate":-0.07584081059634994,"floatShares":11000087,"shares":22711420,"eps":-13.035484,"marketStatus":"Trading","change":-37.275,"latestTime":"02-19 09:34:29 EST","open":452.02,"high":461.5,"low":445.3301,"amount":51491624.51508,"amplitude":0.0329,"askPrice":453.92,"askSize":20,"bidPrice":450,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-13.035484,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":491.49,"preHourTrading":{"tag":"盘前","latestPrice":454.58,"preClose":491.49,"latestTime":"09:29 EST","volume":16434,"amount":7602361.0047,"timestamp":1771511370035,"change":-36.91,"changeRate":-0.075098,"amplitude":0.099697},"postHourTrading":{"tag":"盘后","latestPrice":498.5,"preClose":491.49,"latestTime":"19:59 EST","volume":14398,"amount":7081902.588,"timestamp":1771462782086,"change":7.01,"changeRate":0.014263,"amplitude":0.014263},"volumeRatio":29.264077,"impliedVol":0.5311,"impliedVolPercentile":0.2191},"requestUrl":"/m/hq/s/MDGL/tweets","defaultTab":"tweets","newsList":[{"id":"2612833582","title":"BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2612833582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612833582?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:11","pubTimestamp":1771510280,"startTime":"0","endTime":"0","summary":"BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O down 6% at $462.10 premarket** Co reports Q4 loss of $2.57 per share vs analysts' estimated loss of 40 cents per share - LSEG data** MDGL posts Q4 net revenue of $321.1 million vs estimates of $312.5 million** Truist Securities says \"the 12% Q4 and Q3 revenue growth reflecting consistent progress should aid in providing investor confidence that the company can continue to execute on Rezdiffra\"** As of December 31, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $988.6 million, compared with $931.3 million a year ago** In 2025, MDGL was up 88.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"1161698493","title":"Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1161698493","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161698493?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:24","pubTimestamp":1771503874,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.The biopharmaceutical company reported Q4...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"gpt_icon":0},{"id":"2612543402","title":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2612543402","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612543402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:12","pubTimestamp":1771503137,"startTime":"0","endTime":"0","summary":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"gpt_icon":0},{"id":"2612404089","title":"Madrigal posts FY 2025 net revenues of USD 958.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404089?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:04","pubTimestamp":1771502648,"startTime":"0","endTime":"0","summary":"Madrigal posts FY 2025 net revenues of USD 958.4 million               Madrigal Pharmaceuticals reported Q4 2025 product revenue, net of USD 321.08 million and FY 2025 product revenue, net of USD 958.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL1W3jZ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","MDGL","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4585","LU2210149790.SGD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2612240402","title":"Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612240402","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612240402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:02","pubTimestamp":1771502526,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50714280/madrigal-pharmaceuticals-q4-2025-eps-2-57-misses-0-40-estimate-sales-321-083m-beat-312-490m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2612404444","title":"BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404444","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404444?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502450,"startTime":"0","endTime":"0","summary":"BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57\n\n\nFeb 19 (Reuters) - Madrigal Pharmaceuticals Q4 product revenue USD 321.083 million.\n\nQ4 operating expenses USD 380.692 million\nQ4 net income USD -58.575 million\nQ4 operating income USD -59.609 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","MDGL","BK4139"],"gpt_icon":0},{"id":"2612740419","title":"Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612740419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612740419?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2612404117","title":"Madrigal Pharmaceuticals Q4 Net Income USD -58.575 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612404117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612404117?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","MDGL"],"gpt_icon":0},{"id":"2612041734","title":"Madrigal Pharmaceuticals Q4 Operating Income USD -59.609 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612041734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612041734?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","MDGL","BK4139","BK4585"],"gpt_icon":0},{"id":"2612041084","title":"Madrigal Pharmaceuticals Q4 Operating Expenses USD 380.692 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612041084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612041084?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nPLXFDFD52:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2612556460","title":"Madrigal Pharmaceuticals Grants Equity Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2612556460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612556460?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:05","pubTimestamp":1771362347,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has granted equity awards to five new non-executive employees under its 2025 Inducement Plan. The awards comprise a total of 2,749 time-based restricted stock units, which will vest in four equal installments on each of the first through fourth anniversaries of the grant date, contingent on continued employment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1v5dgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","MDGL","SG9999014021.USD","SG9999014005.SGD","BK4112","LU0314104364.USD","BK4588","NDAQ","BK4139","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2610920308","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Doximity (DOCS) and Humana (HUM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610920308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610920308?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:50","pubTimestamp":1770907821,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL – Research Report),...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-madrigal-pharmaceuticals-mdgl-doximity-docs-and-humana-hum-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-madrigal-pharmaceuticals-mdgl-doximity-docs-and-humana-hum-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","LU0128526141.USD","LABU","BK4581","BK4585","BK4139","BK4588","HCSG","DOCS","MDGL","XLV","BK4551","BK4167","XBI","BK4137","LU0029874061.USD","BK4539"],"gpt_icon":0},{"id":"1165934224","title":"Earning Preview: Madrigal Pharmaceuticals revenue is expected to increase by 217.06%, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1165934224","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165934224?lang=en_us&edition=fundamental","pubTime":"2026-02-12 12:43","pubTimestamp":1770871415,"startTime":"0","endTime":"0","summary":"Abstract Madrigal Pharmaceuticals will publish fourth-quarter and full-year 2025 results on February 19, 2026, Pre-Market, with forecasts pointing to revenue of $312.49 million and an improved loss...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Earning Preview: Madrigal Pharmaceuticals revenue is expected to increase by 217.06%, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2610493993","title":"Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493993?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:25","pubTimestamp":1770809124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA5TLHS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK4588","MDGL","BK4585","BK4139","BK1161"],"gpt_icon":0},{"id":"2610936949","title":"BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936949","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936949?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:02","pubTimestamp":1770807742,"startTime":"0","endTime":"0","summary":"BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna ProgramsFeb 11 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:MADRIGAL EXPANDS ITS MASH PI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA3YMJ0Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2610933985","title":"Madrigal, Suzhou Ribo in license deal for liver‑disease programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933985","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933985?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:10","pubTimestamp":1770804632,"startTime":"0","endTime":"0","summary":"Madrigal, Suzhou Ribo in license deal for liverdisease programsFeb 11  - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs to treat a type of liver disease.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","06938","BK4588","BK1161","MDGL","BK4139"],"gpt_icon":0},{"id":"2610933210","title":"Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933210","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933210?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:10","pubTimestamp":1770804618,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-announces-exclusive-license-pact-with-suzho-ribo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-announces-exclusive-license-pact-with-suzho-ribo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDGL","BK4588","BK4585"],"gpt_icon":0},{"id":"2610933517","title":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933517","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933517?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:09","pubTimestamp":1770804556,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With MadrigalFeb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","MDGL","BK4588","BK4139","06938"],"gpt_icon":0},{"id":"2610333309","title":"Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science","url":"https://stock-news.laohu8.com/highlight/detail?id=2610333309","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610333309?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:03","pubTimestamp":1770804218,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has entered into an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA  programs. This partnership will expand Madrigal’s pipeline for metabolic dysfunction-associated steatohepatitis  by advancing next-generation siRNA therapies that target genes implicated in the disease. The collaboration aims to develop precision gene-silencing treatments to address unmet needs in MASH, complementing Madrigal’s foundational therapy, Rezdiffra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on February 11, 2026, and i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbLh597:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK4585","06938","MDGL","BK4588"],"gpt_icon":0},{"id":"2610338509","title":"Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2610338509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610338509?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","MDGL","BK1161","06938"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0218},{"period":"1month","weight":-0.0203},{"period":"3month","weight":-0.0934},{"period":"6month","weight":0.1852},{"period":"1year","weight":0.4461},{"period":"ytd","weight":-0.156}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.8,"avgChangeRate":0.072907},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.037813},{"month":4,"riseRate":0.555556,"avgChangeRate":0.008622},{"month":5,"riseRate":0.333333,"avgChangeRate":0.130548},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction